XOMA (NASDAQ:XOMA) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of XOMA (NASDAQ:XOMA) in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a $104.00 price objective on the biotechnology company’s stock.

Separately, StockNews.com downgraded shares of XOMA from a “hold” rating to a “sell” rating in a research note on Tuesday, February 25th.

XOMA Stock Up 0.0 %

Shares of NASDAQ:XOMA opened at $20.90 on Wednesday. XOMA has a 1 year low of $19.92 and a 1 year high of $35.00. The business has a 50 day simple moving average of $24.55 and a two-hundred day simple moving average of $27.24. The firm has a market capitalization of $246.26 million, a PE ratio of -6.01 and a beta of 1.00. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52.

XOMA (NASDAQ:XOMA) last posted its quarterly earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.17). XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. The company had revenue of $8.70 million for the quarter, compared to the consensus estimate of $8.75 million. On average, equities analysts predict that XOMA will post -1.41 EPS for the current year.

Insider Activity

In related news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the business’s stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $26.10, for a total value of $13,069,366.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 7.20% of the company’s stock.

Hedge Funds Weigh In On XOMA

A number of large investors have recently bought and sold shares of XOMA. Woodline Partners LP raised its stake in XOMA by 63.9% in the fourth quarter. Woodline Partners LP now owns 156,266 shares of the biotechnology company’s stock worth $4,107,000 after buying an additional 60,927 shares in the last quarter. JPMorgan Chase & Co. raised its stake in XOMA by 238.9% in the fourth quarter. JPMorgan Chase & Co. now owns 12,089 shares of the biotechnology company’s stock worth $318,000 after buying an additional 8,522 shares in the last quarter. Barclays PLC raised its stake in XOMA by 300.7% in the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after buying an additional 8,447 shares in the last quarter. Los Angeles Capital Management LLC purchased a new position in XOMA in the fourth quarter worth $206,000. Finally, Renaissance Technologies LLC grew its holdings in XOMA by 89.8% in the fourth quarter. Renaissance Technologies LLC now owns 16,100 shares of the biotechnology company’s stock worth $423,000 after purchasing an additional 7,619 shares during the last quarter. Institutional investors own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.